Lyell Immunopharma LYEL 深 滬
等待開盤 11-04 09:30:00 美东时间
10.77
-0.110
-1.01%
華盛通- 最 高11.63
- 今 開10.92
- 成交量 7.81万股
- 最 低 10.58
- 昨 收 10.88
- 總市值 2.64亿
- 52周最高 45.00
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 7.195
- 委 比 96.19%
- 總股本 2450.51万
- 歷史最高 396.80
- 量 比 0.60
- 振 幅 9.65%
- 歷史最低 7.195
- 每 手 1
- 風險率 6.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.
11-03 18:14
Lyell Immunopharma收跌1.45%，成交额113.08万美元
11月3日，Lyell Immunopharma（LYEL）收跌1.45%，报10.88美元，成交额113.08万美元，市值2.67亿美元。 行情数据 • 开盘...
11-03 07:28
Lyell Immunopharma To Participate in November Investor Events
Lyell Immunopharma announced that its senior management will participate in three upcoming investor events: Goldman Sachs’ RxChange Series on November 5, 2026; Stifel 2026 Healthcare Conference on November 10, 2026; and the 2026 Jefferies Global Healthcare Conference on November 18, 2026. These events will feature fireside chats and one-on-one meetings. Lyell, a late-stage clinical company, focuses on developing next-generation CAR T-cell therapi...
11-02 13:00
Lyell Immunopharma收跌0.85%，成交额78.67万美元
10月27日，Lyell Immunopharma（LYEL）收跌0.85%，报9.31美元，成交额78.67万美元，市值2.28亿美元。 行情数据 • 开盘价...
10-27 06:36
Lyell Immunopharma收跌0.85%，成交额159.65万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:44
美股大行评级 | Adobe绩后获多家大行齐升目标价！最高看多至270美元；甲骨文绩后现多空分歧
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从10美元升至10.5美元；摩根士丹利：维持Aurora Innovation"超配"评级，目标价从14美元升至18美元
09-14 16:05
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.
09-11 19:17
Lyell Immunopharma advances LYL273 CAR T program
Lyell Immunopharma ( ($LYEL) ) has issued an update. On September 10, 2026, Lye...
09-11 04:29
Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced successful completion of the planned technology transfer for LYL273, a guanylyl cyclase C (GCC)-ta...
09-11 04:07
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Lyell Immunopharma announced the successful completion of technology transfer for LYL273 to its LyFE Manufacturing Center following FDA review. The Phase 1/2 trial continues with additional patients dosed using the improved manufacturing process to determine the recommended Phase 2 dose and optimize safety management. Additional clinical data and an End-of-Phase 1 FDA meeting are expected in 2027. LYL273 is a CAR T-cell therapy targeting metastat...
09-10 20:05
